查詢結果分析
相關文獻
- 單株抗體用於多發性硬化症之治療
- 多發性硬化症之藥物治療簡介
- Detection of Oligocolonal Bands in Patients with Neurologic Diseases: Comparison between Agarose Gel-,Immunofixation-and Isoelectric-Focusing Electrophoresis
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 多發性硬化症之血液析離療法
- 豬生殖與呼吸綜合症病毒「gp5重組蛋白」的表現與單株抗體之製備
- Multiple Sclerosis in Children: Clinical, Neuroimaging, and Neurophysiological Correlations
- Utilization of Monoclonal and Polyclonal Antibodies to Monitor the Protecting and Challenging Strains of Zucchini Yellow Mosaic Virus in Cross Protection
- 有眩暈症狀的多發性硬化症--病例報告
- 單株抗體製備
頁籤選單縮合
題名 | 單株抗體用於多發性硬化症之治療=Monoclonal Antibodies in Multiple Sclerosis |
---|---|
作者 | 郭瓊文; 江吉文; 張銘顯; 黃耀斌; | 書刊名 | 藥學雜誌 |
卷期 | 27:2=107 2011.06[民100.06] |
頁次 | 頁27-32 |
分類號 | 418.29 |
關鍵詞 | 多發性硬化症; 單株抗體; |
語文 | 中文(Chinese) |
中文摘要 | 「多發性硬化症」 (multiple sclerosis,以下簡稱 MS)是一種中樞神經系統 (指大腦和脊髓 )自體免疫疾病,其致病性與 T細胞、 B細胞誘發發炎相關免疫反應,因此將單株抗體 (monoclonal antibodies,以下簡稱 mAbs)應用於 MS治療,針對免疫系統中特定標的細胞來作用,藉由免疫抑制方式使淋巴細胞 (T細胞、 B細胞和巨噬細胞 )數量減少,降低對自體抗體對於中樞神經系統破壞。 本文將介紹四種 mAb藥物 (natalizumab、rituximab、alemtuzumab、daclizumab)於多發性硬化症之治療,對於 mAbs與標的細胞作用後可影響免疫反應、中樞神經系統相關發炎過程以及臨床反應等作回顧。 |
英文摘要 | Multiple sclerosis (MS) is an immune-mediated disorder of the brain and spinal cord in which at least part of the inflammatory process. MS suggesting that pathogenic T cells are sufficient for full expression of multiple sclerosis, it is now evident that autoimmune B cells and humoral immune mechanisms also play key roles. The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of MS.The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。